Thales today announced the launch of Thales File Activity Monitoring, a powerful new capability within the Thales CipherTrust Data Security Platform that enhances enterprise visibility and control over unstructured data, enabling organizations to monitor file activity in real time, detect misuse, and ensure regulatory compliance across their entire data estate. As the only integrated platform provider that secures structured and unstructured data, Thales provides comprehensive monitoring and au...

IQM Quantum Computers in collaboration with analyst firm Omdia (LON:INF), today unveiled the third edition of its State of Quantum Report, revealing that the quantum industry must address talent shortages and software development kits (SDK) gaps in order to scale beyond just qubit count. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610552224/en/IQM State of Quantum 2025 Report As quantum computing shifts from theoretical promis...

Clearwater Analytics (NYSE: CWAN), the most comprehensive technology platform for investment management, today announced that Pool Re, the UK’s terrorism reinsurer overseeing more than £7.2 billion in assets, has selected Clearwater to modernize its investment operations, accounting, and risk management infrastructure. After a 2024 tender process, Pool Re adopted Clearwater’s platform as its Investment Accounting Book of Record and has since expanded its use to include advanced risk analytics...

Textron Aviation today celebrated the five-year anniversary of the first flight of the versatile Cessna SkyCourier, the company’s clean-sheet twin-engine, high-wing utility turboprop. This is a significant milestone for this high-performing aircraft which has become a trusted asset for operators worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520930130/en/Cessna SkyCourier marks five years since first flight of clean-she...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, presented results from its DAZALS study of dazucorilant in patients with ALS at the European Network to Cure ALS (ENCALS) 2025 annual meeting. The presentation can be found here. This press release features...